Exiqon enters multimillion agreement with US Genomics  

2004.04.21
The Danish biotech company has entered a multimillion agreement with US Genomics concerning Exiqon's LNA technology

Biotech company Exiqon has entered a multimillion agreement with US Genomics concerning Exiqon's Locked Nucleic Acid (LNA) technology. US Genomics develops technologies for direct analysis of single molecules of biological significance for the life science industry. Exiqon's technology will be used in US Genomics' new product for single molecule detection planned to be launched later this year.

 

Exiqon was founded in 1996 and is based in Vedbæk north of Copenhagen. Investors include Scandinavian Life Science Venture, Teknoinvest, Nobel Group and the Employees Capital Pension Fund. The news is reported by BiotechDenmark online.

 

Link > Exiqon 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×